Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation

Plain-language summary

This observational study examined the genetic subtypes of early-onset atrial fibrillation (a type of heart rhythm disorder) and how they relate to clinical characteristics. It enrolled patients diagnosed with atrial fibrillation before age 65 who met certain criteria based on genetic testing results. This study has no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Vanderbilt University Medical Center

Intervention

None/Observational Studies

Start date

4/27/2022

Estimated completion

3/3/2026

Countries

United States

Related genes

Locations

• Nashville, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Minors \>15 years
* Adult \> 18 years
* Able to provide written informed consent
* Previously enrolled in the Vanderbilt Atrial Fibrillation Registry (IVR#020669)
* Atrial Fibrillation Ablation Registry (IRB#110881)
* Early-onset Atrial Fibrillation Registry (IRB#201666)
* Underwent whole genome sequencing/whole exome sequencing or clinical genetic testing and based on those results meets the genetic criteria for cases and controls as defined as a Cardiomyopathy (CM) Rare Variant (P/LP rare variant in CM gene, Arrhythmia Rare Variant (P/LP rare variant in arrhythmia gene), or a Control (no rare variant in CM, arrhythmia, or other Atrial Fibrillation gene).
* Diagnosis of Atrial Fibrillation prior to age of 65 (\</=65)

Exclusion Criteria:

-Pregnant women